Ribavirin

Generic Name
Ribavirin
Brand Names
Ibavyr, Rebetol, Virazole
Drug Type
Small Molecule
Chemical Formula
C8H12N4O5
CAS Number
36791-04-5
Unique Ingredient Identifier
49717AWG6K
Background

Producing a broad-spectrum activity against several RNA and DNA viruses, Ribavirin is a synthetic guanosine nucleoside and antiviral agent that interferes with the synthesis of viral mRNA. It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes...

Indication

Indicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates .
...

Associated Conditions
Chronic Hepatitis C Virus (HCV) Infection, Severe Respiratory Syncytial Virus Infection
Associated Therapies
-
Clinical Trials
Related News

Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)

Phase 3
Completed
Conditions
Chronic Hepatitis C
First Posted Date
2005-09-12
Last Posted Date
2007-04-24
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
100
Registration Number
NCT00158496
Locations
🇪🇬

National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt

🇪🇬

Ismail Sallam hospital, Zawiat Razin, Menoufia, Egypt

Treatment of Recurrent Hepatitis C After Liver Transplantation

First Posted Date
2005-09-09
Last Posted Date
2012-05-21
Lead Sponsor
Rennes University Hospital
Target Recruit Count
200
Registration Number
NCT00151580
Locations
🇫🇷

Service de Chirurgie Générale et Digestive - Hôpital Cochin, Paris, France

🇫🇷

Service de Chirurgie Digestive - Groupe Hospitalier Pellerin-Tripode, Bordeaux, France

🇫🇷

Service d'Hépatologie - Hôpital Jean Minjoz, Besancon, France

and more 13 locations

HEPMET-1: Evaluate the Feasibility, Mental Sideeffects and the Efficacy of Hepatitis C Treatment in a MMT Group.

Phase 3
Completed
Conditions
Opiate Dependence
Hepatitis
First Posted Date
2005-09-07
Last Posted Date
2008-03-28
Lead Sponsor
Sorlandet Hospital HF
Target Recruit Count
10
Registration Number
NCT00147784
Locations
🇳🇴

Addiction Unit, Sorlandet Hospital, Kristiansand, Vest-Agder, Norway

🇳🇴

Soerlandet Hospital HF, Kristiansand, Vest-Agder, Norway

Escitalopram for the Prevention of PEGASYS-associated Depression in Hepatitis C Virus-infected Patients

First Posted Date
2005-08-29
Last Posted Date
2013-03-21
Lead Sponsor
Charite University, Berlin, Germany
Target Recruit Count
208
Registration Number
NCT00136318
Locations
🇩🇪

Department of Gastroenterolgy and Rheumatology, Sektion Hepatology, Leipzig, Germany

Triple Therapy With Peg-Interferon Alfa-2b/Ribavirin Plus Amantadine Compared to Standard Peg-Interferon Alfa-2b/Ribavirin for Previous Hepatitis C Virus (HCV) Non Responders

Phase 3
Terminated
Conditions
Hepatitis C, Chronic
First Posted Date
2005-07-22
Last Posted Date
2005-07-29
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
405
Registration Number
NCT00122629
Locations
🇫🇷

Service d'Hépato-Gastroentérologie Hopital Hotel Dieu, Lyon Cedex, France

Efficacy of Pegylated Interferon on Liver Fibrosis in Co-infected Patient With HIV and Hepatitis C

First Posted Date
2005-07-22
Last Posted Date
2012-02-22
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
52
Registration Number
NCT00122616
Locations
🇫🇷

Service de Maladies Infectieuses et de Réanimation Médicale, Rennes, France

Valopicitabine Alone and Together With Pegylated Interferon in Patients With Chronic Hepatitis C Who Have Failed to Respond to Standard Therapy

Phase 2
Completed
Conditions
Chronic Hepatitis C
First Posted Date
2005-07-19
Last Posted Date
2010-06-10
Lead Sponsor
Merck Sharp & Dohme LLC
Registration Number
NCT00120861

A Study of Albuferon and Ribavirin in Interferon Naive Subjects With Chronic Hepatitis C Genotype 1

Phase 2
Completed
Conditions
Hepatitis C, Chronic
First Posted Date
2005-06-27
Last Posted Date
2013-11-07
Lead Sponsor
Human Genome Sciences Inc.
Target Recruit Count
458
Registration Number
NCT00115908
Locations
🇷🇴

Spitalul de Boli Infectioase si Tropicale "Dr. Victor Babes", Bucharest, Romania

🇨🇿

Klinika infekcnich nemoci, Hradec Kralove, Czech Republic

🇨🇿

Fakultni Thomayerova nemocnice, Prague, Czech Republic

and more 83 locations

48 Weeks Combination Therapy for Patients With HBeAg-negative Chronic Hepatitis B Virus (HBV) Infection

Phase 3
Completed
Conditions
Hepatitis B
Interventions
Drug: Peginterferon alpha 2a
Drug: Ribavirin
First Posted Date
2005-06-15
Last Posted Date
2010-06-22
Lead Sponsor
Foundation for Liver Research
Target Recruit Count
138
Registration Number
NCT00114361
Locations
🇳🇱

Erasmus MC department hepatology, Rotterdam, Netherlands

Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.

First Posted Date
2005-04-07
Last Posted Date
2016-06-21
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
569
Registration Number
NCT00107653
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy